FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163608347> ?p ?o ?g. }

• W2163608347 endingPage "144" @default.
• W2163608347 startingPage "137" @default.
• W2163608347 abstract "The efficacy of the combination of pyrimethamine and sulfadiazine for the treatment of congenital Toxoplasma gondii infection in rhesus monkeys was studied. The dosage regimen for pyrimethamine and sulfadiazine was established by pharmacokinetic studies in two monkeys. Those studies showed that the distributions of both drugs followed a one-compartment model. The serum elimination half-lives were found to be 5.2 h for sulfadiazine and 44.4 h for pyrimethamine. Sulfadiazine reached a maximum concentration in serum of 58.7 micrograms/ml, whereas a maximum concentration in serum of 0.22 micrograms/ml was found for pyrimethamine. Ten monkeys were infected intravenously with T. gondii at day 90 of pregnancy, which is comparable to the second trimester of organogenetic development in humans. Treatment was administered to six monkeys, in whose fetuses infection was diagnosed antenatally. From the moment that fetal infection was proven, the monkeys were treated throughout pregnancy with 1 mg of pyrimethamine per kg of body weight per day and 50 mg of sulfadiazine per kg of body weight per day orally. The therapy was supplemented with 3.5 mg of folinic acid once a week. No toxic side effects were found with this drug regimen. The parasite was no longer detectable in the next consecutive amniotic fluid sample, taken 10 to 13 days after treatment was started. Furthermore, T. gondii was also not found in the neonate at birth. The parasite was still present at birth in three of four untreated fetuses that served as controls. Both drugs crossed the placenta very well. Concentrations in fetal serum varied from 0.05 to 0.14 micrograms/ml for pyrimethamine and from 1.0 to 5.4 micrograms/ml for sulfadiazine. In addition, pyrimethamine was found to accumulate in the brain tissue, with concentrations being three to four times higher than the corresponding concentrations in serum. Thirty percent of the sulfadiazine was found to reach the brain tissue when compared with the corresponding serum concentration. when administered early after the onset of infection, the combination of pyrimethamine and sulfadiazine was clearly effective in reducing the number of parasites in the fetus to undetectable levels." @default.
• W2163608347 created "2016-06-24" @default.
• W2163608347 creator A5026045883 @default.
• W2163608347 creator A5026072189 @default.
• W2163608347 creator A5028475220 @default.
• W2163608347 creator A5030273508 @default.
• W2163608347 creator A5049842739 @default.
• W2163608347 creator A5054798761 @default.
• W2163608347 creator A5077205584 @default.
• W2163608347 creator A5090407835 @default.
• W2163608347 date "1995-01-01" @default.
• W2163608347 modified "2023-10-10" @default.
• W2163608347 title "Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine" @default.
• W2163608347 cites W107881379 @default.
• W2163608347 cites W1833207062 @default.
• W2163608347 cites W1927618215 @default.
• W2163608347 cites W1949182617 @default.
• W2163608347 cites W1963535021 @default.
• W2163608347 cites W1969100634 @default.
• W2163608347 cites W1974137593 @default.
• W2163608347 cites W1989646684 @default.
• W2163608347 cites W1995054522 @default.
• W2163608347 cites W1997900644 @default.
• W2163608347 cites W1998009462 @default.
• W2163608347 cites W1998157791 @default.
• W2163608347 cites W2003682354 @default.
• W2163608347 cites W2008299205 @default.
• W2163608347 cites W2008318827 @default.
• W2163608347 cites W2012695904 @default.
• W2163608347 cites W2022310297 @default.
• W2163608347 cites W2023174165 @default.
• W2163608347 cites W2027127607 @default.
• W2163608347 cites W2041158483 @default.
• W2163608347 cites W2052997048 @default.
• W2163608347 cites W2070914270 @default.
• W2163608347 cites W2091043696 @default.
• W2163608347 cites W2103455903 @default.
• W2163608347 cites W2146861732 @default.
• W2163608347 cites W2154682659 @default.
• W2163608347 cites W2166229810 @default.
• W2163608347 cites W2207230444 @default.
• W2163608347 cites W2286777858 @default.
• W2163608347 cites W2327903814 @default.
• W2163608347 cites W2328289254 @default.
• W2163608347 cites W2337270963 @default.
• W2163608347 cites W2405887065 @default.
• W2163608347 cites W2411083874 @default.
• W2163608347 cites W2411625090 @default.
• W2163608347 cites W2412961590 @default.
• W2163608347 cites W2416267174 @default.
• W2163608347 cites W2418358887 @default.
• W2163608347 cites W2418369132 @default.
• W2163608347 cites W2424165516 @default.
• W2163608347 cites W272970896 @default.
• W2163608347 cites W2117119793 @default.
• W2163608347 cites W2470994990 @default.
• W2163608347 cites W2485822555 @default.
• W2163608347 cites W2517515720 @default.
• W2163608347 doi "https://doi.org/10.1128/aac.39.1.137" @default.
• W2163608347 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/162499" @default.
• W2163608347 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7695295" @default.
• W2163608347 hasPublicationYear "1995" @default.
• W2163608347 type Work @default.
• W2163608347 sameAs 2163608347 @default.
• W2163608347 citedByCount "34" @default.
• W2163608347 countsByYear W21636083472014 @default.
• W2163608347 countsByYear W21636083472018 @default.
• W2163608347 countsByYear W21636083472020 @default.
• W2163608347 countsByYear W21636083472021 @default.
• W2163608347 countsByYear W21636083472022 @default.
• W2163608347 crossrefType "journal-article" @default.
• W2163608347 hasAuthorship W2163608347A5026045883 @default.
• W2163608347 hasAuthorship W2163608347A5026072189 @default.
• W2163608347 hasAuthorship W2163608347A5028475220 @default.
• W2163608347 hasAuthorship W2163608347A5030273508 @default.
• W2163608347 hasAuthorship W2163608347A5049842739 @default.
• W2163608347 hasAuthorship W2163608347A5054798761 @default.
• W2163608347 hasAuthorship W2163608347A5077205584 @default.
• W2163608347 hasAuthorship W2163608347A5090407835 @default.
• W2163608347 hasBestOaLocation W21636083472 @default.
• W2163608347 hasConcept C112705442 @default.
• W2163608347 hasConcept C126322002 @default.
• W2163608347 hasConcept C159654299 @default.
• W2163608347 hasConcept C172680121 @default.
• W2163608347 hasConcept C203014093 @default.
• W2163608347 hasConcept C2776694085 @default.
• W2163608347 hasConcept C2777035104 @default.
• W2163608347 hasConcept C2777425658 @default.
• W2163608347 hasConcept C2778048844 @default.
• W2163608347 hasConcept C2778062946 @default.
• W2163608347 hasConcept C2778128430 @default.
• W2163608347 hasConcept C2778269047 @default.
• W2163608347 hasConcept C2779234561 @default.
• W2163608347 hasConcept C2779804826 @default.
• W2163608347 hasConcept C2780456651 @default.
• W2163608347 hasConcept C2781413609 @default.
• W2163608347 hasConcept C42407357 @default.
• W2163608347 hasConcept C501593827 @default.

• next